drugset
drugset / Trial / NCT01000311

A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

NCT01000311 ↗

Phase 3 Completed 529 enrolled Novartis Vaccines
RandomizedParallel-groupOpen-labelPrevention

Summary

This Phase 3 study is designed to demonstrate the safety and immunogenicity of MenACWY and non-interference of concomitant routine vaccines by MenACWY in an infant age group.

Timeline

Start
2009-11
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Menveo Vaccine 0.5 ml Intramuscular
Background DTaP-IPV/Hib Unknown 0.5 ml Intramuscular
Background HBV Unknown 0.5 ml Intramuscular
Background MMR Unknown 0.5 ml Subcutaneous
Background PCV Unknown 0.5 ml Intramuscular

Indications

meningococcal infection